CN1679562A - 抗病毒大环化合物 - Google Patents
抗病毒大环化合物 Download PDFInfo
- Publication number
- CN1679562A CN1679562A CNA2005100094866A CN200510009486A CN1679562A CN 1679562 A CN1679562 A CN 1679562A CN A2005100094866 A CNA2005100094866 A CN A2005100094866A CN 200510009486 A CN200510009486 A CN 200510009486A CN 1679562 A CN1679562 A CN 1679562A
- Authority
- CN
- China
- Prior art keywords
- methylene
- disease
- purposes
- chemical compound
- phenylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- AIDS & HIV (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
表1 | ||||
抗HIV活性数据 | ||||
化合物 | CC50(ug/mL) | EC50(ug/mL) | SI | |
HIV-1(IIIB) | HIV-2 | HIV-1 | ||
1AMD3465 | >250 | 0.008 | 0.032 | 3×104 |
2AMD3538 | 209 | 0.1 | 6.7 | 2.0×103 |
3AMD3500 | >250 | 0.6 | 10.3 | 417 |
4AMD3499 | >250 | 1.8 | 28.5 | 138 |
5AMD3498 | >250 | 0.2 | 7.1 | 1.2×103 |
6AMD3497 | >250 | 1.8 | 3.8 | 138 |
7AMD3516 | 158 | 0.7 | 9.8 | 225 |
8AMD3530 | 175 | 0.5 | 2.0 | 350 |
9AMD3517 | 153 | 0.8 | 10.6 | 191 |
10AMD3544 | 222 | 0.7 | 3.7 | 317 |
11AMD3543 | 239 | 0.2 | 1.0 | 1×103 |
12AMD3529 | 130 | 0.4 | 2.6 | 325 |
化合物 | 对mAb 12G5结合的抑制IC50 a(ng/ml) |
AMD3100 | 27 |
AMD3465 | 3 |
AMD7049 | 52 |
AMD7050 | 1 |
AMD7051 | 7 |
AMD7058 | >1000 |
AMD7059 | >1000 |
AMD7063 | 9 |
SDF-1αb | 270 |
化合物 | %对Ca2+流动(浓度)或IC50 a(ng/ml)的抑制 |
AMD3100 | 5 |
AMD3465 | 1 |
AMD7049 | 100%(1μg/ml) |
AMD7050 | 100%(1μg/ml) |
AMD7051 | 100%(1μg/ml) |
AMD7058 | 44%(1μg/ml) |
AMD7059 | 36%(1μg/ml) |
AMD7063 | 100%(1μg/ml) |
化合物 | IC50 a(μg/mL) |
AMD3451 | 8.9 |
AMD3472 | 45.4 |
AMD3454 | 32.3 |
AMD3526 | 82 |
AMD3100 | >100 |
Claims (20)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/111,895 | 1998-07-08 | ||
US09/111,895 US6506770B1 (en) | 1996-06-06 | 1998-07-08 | Antiviral compounds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998082600A Division CN1195745C (zh) | 1998-07-08 | 1999-07-08 | 抗病毒大环化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1679562A true CN1679562A (zh) | 2005-10-12 |
CN100339080C CN100339080C (zh) | 2007-09-26 |
Family
ID=22341015
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100094866A Expired - Lifetime CN100339080C (zh) | 1998-07-08 | 1999-07-08 | 抗病毒大环化合物 |
CNB998082600A Expired - Fee Related CN1195745C (zh) | 1998-07-08 | 1999-07-08 | 抗病毒大环化合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998082600A Expired - Fee Related CN1195745C (zh) | 1998-07-08 | 1999-07-08 | 抗病毒大环化合物 |
Country Status (17)
Country | Link |
---|---|
US (6) | US6506770B1 (zh) |
EP (1) | EP1095031B1 (zh) |
JP (1) | JP4637353B2 (zh) |
KR (1) | KR100778134B1 (zh) |
CN (2) | CN100339080C (zh) |
AP (1) | AP1436A (zh) |
AU (1) | AU767359B2 (zh) |
BR (1) | BR9912524A (zh) |
CA (1) | CA2336634C (zh) |
HU (1) | HUP0102930A3 (zh) |
IL (1) | IL140605A0 (zh) |
MX (1) | MXPA01000137A (zh) |
NO (1) | NO20010047L (zh) |
NZ (1) | NZ509699A (zh) |
PL (1) | PL345516A1 (zh) |
TR (1) | TR200100030T2 (zh) |
WO (1) | WO2000002870A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112569242A (zh) * | 2015-04-02 | 2021-03-30 | 普罗克斯马根有限责任公司 | 用于癌症的新治疗 |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9511357D0 (en) * | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
US20050085555A1 (en) * | 1997-08-21 | 2005-04-21 | Murphy Michael A. | Composition, synthesis and therapeutic applications of polyamines |
US6365583B1 (en) * | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
ATE428706T1 (de) * | 1999-12-17 | 2009-05-15 | Genzyme Corp | Chemokinrezeptor-bindende heterocyclische verbindungen |
MXPA03002325A (es) * | 2000-09-15 | 2003-06-24 | Anormed Inc | Compuestos heterociclicos que se unen a receptor de quimiocina. |
US7052676B2 (en) * | 2000-09-26 | 2006-05-30 | The Regents Of The University Of Michigan | Methods for inhibition of HIV replication using a small molecule inhibitor |
US7169750B2 (en) | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
LT2371361T (lt) | 2001-07-31 | 2019-09-10 | Genzyme Corporation | Pirmtakų/kamieninių ląstelių suaktyvinimo būdai |
US7354932B2 (en) * | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
WO2003055876A1 (en) * | 2001-12-21 | 2003-07-10 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US20030199464A1 (en) * | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
JP3949708B2 (ja) | 2003-04-02 | 2007-07-25 | タイゲン・バイオテクノロジー | ケモカイン受容体介在疾患を治療するためのポリアミン化合物 |
US7504422B2 (en) | 2003-04-02 | 2009-03-17 | Taigen Biotechnology Co. Ltd. | Polyamine compounds |
WO2004091518A2 (en) | 2003-04-11 | 2004-10-28 | Anormed Inc. | Cxcr4 chemokine receptor binding compounds |
WO2004093817A2 (en) | 2003-04-22 | 2004-11-04 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US7501518B2 (en) | 2003-04-22 | 2009-03-10 | Genzyme Corporation | Methods of making 2,6-diaryl piperidine derivatives |
JPWO2005051927A1 (ja) * | 2003-11-26 | 2007-12-06 | 株式会社クレハ | Hiv−1感染末梢血単核球の刺激培養によるcd4陽性t細胞の培養方法、及びhiv−1の増殖阻害剤 |
BRPI0514343A (pt) * | 2004-08-13 | 2008-06-10 | Anormed Inc | combinações de quimiocinas para mobilizar células progenitoras/tronco |
US7501526B2 (en) | 2005-01-20 | 2009-03-10 | Taigen Biotechnology | Synthesis of polyamine compounds |
US7825088B2 (en) * | 2005-04-25 | 2010-11-02 | The Cbr Institute For Biomedical Research, Inc. | Methods for the treatment of multiple myeloma |
US8569280B2 (en) * | 2005-04-25 | 2013-10-29 | Immune Disease Institute | Methods for the treatment of multiple myeloma |
US20070043012A1 (en) * | 2005-08-19 | 2007-02-22 | Bridger Gary J | Methods to enhance chemotherapy |
CA2624138A1 (en) * | 2005-09-29 | 2007-04-05 | British Columbia Cancer Agency Branch | Method and composition for increasing the engraftment efficiency of stem cells |
EP2397148A3 (en) | 2006-02-02 | 2012-04-25 | Allergan, Inc. | Compositions and methods for the treatment of ophthalmic disease |
US20090247570A1 (en) * | 2006-06-12 | 2009-10-01 | Pfizer Inc | Pharmaceuticals |
RU2009107030A (ru) * | 2006-08-02 | 2010-09-10 | Джензим Корпорейшн (Us) | Комбинированная терапия |
AR062271A1 (es) * | 2006-08-07 | 2008-10-29 | Genzyme Corp | Uso de una cantidad efectiva de al menos un inhibidor de cxcr4, al menos un agonista de cxcr2 y g-csf para movilizar las celulas progenitoras y/o celulas madre |
US20090274687A1 (en) * | 2008-05-02 | 2009-11-05 | University Of Miami | Attenuation of hypoxia induced cardiovascular disorders |
WO2010088401A1 (en) * | 2009-01-30 | 2010-08-05 | Genzyme Corporation | Methods and compositions for treating breast cancer |
CA2760292A1 (en) * | 2009-05-01 | 2010-11-04 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
WO2012037034A1 (en) | 2010-09-14 | 2012-03-22 | Glycomimetics, Inc. | E-selectin antagonists |
GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
WO2012061662A1 (en) * | 2010-11-03 | 2012-05-10 | Glycomimetics, Inc. | Glycomimetic-peptidomimetic inhibitors of e-selectins and cxcr4 chemokine receptors |
KR20210094672A (ko) | 2011-05-16 | 2021-07-29 | 젠자임 코포레이션 | Cxcr4 길항제의 용도 |
CN103159690B (zh) * | 2011-12-14 | 2015-03-25 | 朱靖华 | 对称大环胺化合物的结晶形式 |
JP2015500887A (ja) | 2011-12-22 | 2015-01-08 | グリコミメティクス, インコーポレイテッド | E−セレクチンアンタゴニスト化合物、組成物および使用方法 |
AU2013355238B2 (en) | 2012-12-07 | 2017-12-14 | Glycomimetics, Inc. | Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells |
CN103058998B (zh) * | 2013-01-16 | 2016-04-13 | 山东鲁北药业有限公司 | 一种amd3465的制备工艺 |
SI3227310T1 (sl) | 2014-12-03 | 2019-11-29 | Glycomimetics Inc | Heterobifunkcionalni inhibitorji e-selektinov in receptorjev kemokina CXCR4 |
US10709697B2 (en) | 2015-07-16 | 2020-07-14 | Emory University | Bis-amines, compositions, and uses related to CXCR4 inhibition |
EP3364965A4 (en) * | 2015-10-19 | 2019-06-26 | Ramot at Tel-Aviv University Ltd. | METHOD AND COMPOSITIONS FOR TREATING NEURODEEGENERATIVE DISEASES |
ES2907489T3 (es) | 2015-12-14 | 2022-04-25 | X4 Pharmaceuticals Inc | Métodos para el tratamiento del cáncer |
CN109069486A (zh) | 2015-12-14 | 2018-12-21 | X4 制药有限公司 | 治疗癌症的方法 |
CN108883091A (zh) | 2015-12-22 | 2018-11-23 | X4 制药有限公司 | 用于治疗免疫缺陷病的方法 |
US11291678B2 (en) | 2016-03-02 | 2022-04-05 | Glycomimetics, Inc | Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin |
JP2019510785A (ja) | 2016-04-08 | 2019-04-18 | エックス4 ファーマシューティカルズ, インコーポレイテッド | 癌を処置する方法 |
US11433048B2 (en) | 2016-06-16 | 2022-09-06 | Centre National De La Recherche Scientifique | CXCR4 receptor-binding compounds useful for increasing interferon level |
CA3027495A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
US11332470B2 (en) | 2016-06-21 | 2022-05-17 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
CN116554168A (zh) | 2016-06-21 | 2023-08-08 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
WO2018031445A1 (en) | 2016-08-08 | 2018-02-15 | Glycomimetics, Inc. | Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4 |
JP7069136B2 (ja) | 2016-10-07 | 2022-05-17 | グリコミメティクス, インコーポレイテッド | 極めて強力な多量体e-セレクチンアンタゴニスト |
EP3596096A1 (en) | 2017-03-15 | 2020-01-22 | GlycoMimetics, Inc. | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists |
AU2018358241A1 (en) | 2017-10-31 | 2020-05-07 | Edigene Biotechnology, Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells |
WO2019089833A1 (en) | 2017-10-31 | 2019-05-09 | Magenta Therapeutics Inc. | Compositions and methods for hematopoietic stem and progenitor cell transplant therapy |
JP7275131B2 (ja) | 2017-11-30 | 2023-05-17 | グリコミメティクス, インコーポレイテッド | 骨髄浸潤リンパ球を動員する方法、およびその使用 |
JP2021505172A (ja) | 2017-12-06 | 2021-02-18 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | 造血幹細胞及び前駆細胞を動員させるための投薬レジメン |
US10058573B1 (en) | 2017-12-06 | 2018-08-28 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem cells |
US11260079B2 (en) | 2017-12-06 | 2022-03-01 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
CN111566117A (zh) | 2017-12-29 | 2020-08-21 | 糖模拟物有限公司 | E-选择蛋白和半乳凝素-3的异双功能抑制剂 |
CN109988153B (zh) * | 2017-12-29 | 2021-11-19 | 深圳夏浠湾医药科技有限公司 | 一种川芎嗪衍生物及其制备方法和应用 |
CN111902411A (zh) | 2018-01-03 | 2020-11-06 | 美真达治疗公司 | 用于扩增造血干细胞和祖细胞以及治疗遗传性代谢紊乱的组合物和方法 |
JP7455064B2 (ja) | 2018-03-05 | 2024-03-25 | グリコミメティクス, インコーポレイテッド | 急性骨髄性白血病および関連状態を処置する方法 |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
WO2020139962A1 (en) | 2018-12-27 | 2020-07-02 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectin and galectin-3 |
EP4051298A1 (en) | 2019-11-01 | 2022-09-07 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progentor cells |
CA3176979A1 (en) | 2020-04-27 | 2021-11-04 | Anthony Boitano | Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo |
EP4308694A1 (en) | 2021-03-16 | 2024-01-24 | Magenta Therapeutics, Inc. | Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5021409A (en) | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
GB9105489D0 (en) | 1991-03-15 | 1991-05-01 | Johnson Matthey Plc | Improvements in chemical compounds |
GB9126677D0 (en) * | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
WO2000009152A1 (en) | 1998-08-14 | 2000-02-24 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
ATE258444T1 (de) | 1998-03-13 | 2004-02-15 | Univ British Columbia | Therapeutische chemokine rezeptor antagonisten |
ES2268854T3 (es) * | 1998-03-24 | 2007-03-16 | Chugai Seiyaku Kabushiki Kaisha | Inhibidores de la vascularizacion. |
WO1999065507A1 (en) | 1998-06-19 | 1999-12-23 | The General Hospital Corporation | Modulating platelet function |
AU5241099A (en) * | 1998-07-31 | 2000-02-21 | Trustees Of Columbia University In The City Of New York, The | Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis |
US6365583B1 (en) | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
WO2005002522A2 (en) | 2003-06-30 | 2005-01-13 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Compositions and methods for treating tissue ischemia |
US7315917B2 (en) * | 2005-01-20 | 2008-01-01 | Sandisk Corporation | Scheduling of housekeeping operations in flash memory systems |
-
1998
- 1998-07-08 US US09/111,895 patent/US6506770B1/en not_active Expired - Lifetime
-
1999
- 1999-07-08 KR KR1020017000220A patent/KR100778134B1/ko not_active IP Right Cessation
- 1999-07-08 JP JP2000559101A patent/JP4637353B2/ja not_active Expired - Lifetime
- 1999-07-08 PL PL99345516A patent/PL345516A1/xx not_active Application Discontinuation
- 1999-07-08 IL IL14060599A patent/IL140605A0/xx unknown
- 1999-07-08 CN CNB2005100094866A patent/CN100339080C/zh not_active Expired - Lifetime
- 1999-07-08 AU AU45959/99A patent/AU767359B2/en not_active Expired
- 1999-07-08 EP EP99928956.4A patent/EP1095031B1/en not_active Expired - Lifetime
- 1999-07-08 CN CNB998082600A patent/CN1195745C/zh not_active Expired - Fee Related
- 1999-07-08 TR TR2001/00030T patent/TR200100030T2/xx unknown
- 1999-07-08 BR BR9912524-2A patent/BR9912524A/pt not_active Application Discontinuation
- 1999-07-08 CA CA002336634A patent/CA2336634C/en not_active Expired - Fee Related
- 1999-07-08 AP APAP/P/2001/002043A patent/AP1436A/en active
- 1999-07-08 NZ NZ509699A patent/NZ509699A/en not_active IP Right Cessation
- 1999-07-08 WO PCT/CA1999/000619 patent/WO2000002870A1/en active IP Right Grant
- 1999-07-08 HU HU0102930A patent/HUP0102930A3/hu unknown
- 1999-07-08 MX MXPA01000137A patent/MXPA01000137A/es active IP Right Grant
- 1999-07-08 US US09/743,561 patent/US6872714B1/en not_active Expired - Lifetime
-
2001
- 2001-01-04 NO NO20010047A patent/NO20010047L/no not_active Application Discontinuation
-
2002
- 2002-05-09 US US10/143,692 patent/US6756391B2/en not_active Expired - Lifetime
-
2004
- 2004-06-21 US US10/872,735 patent/US7160872B2/en not_active Expired - Fee Related
- 2004-11-17 US US10/991,944 patent/US7414065B2/en not_active Expired - Fee Related
-
2008
- 2008-07-29 US US12/182,044 patent/US7709486B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112569242A (zh) * | 2015-04-02 | 2021-03-30 | 普罗克斯马根有限责任公司 | 用于癌症的新治疗 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100339080C (zh) | 抗病毒大环化合物 | |
CN1134420C (zh) | 新的取代咪唑化合物 | |
CN1138546C (zh) | 用作细胞因子的某些1,4,5-三取代咪唑化合物 | |
CN1305872C (zh) | 喹唑啉类化合物的制备方法 | |
CN1044117C (zh) | 用于抑制人免疫缺陷病毒蛋白酶的化合物及其制备方法和药物用途 | |
CN1304375C (zh) | 用作jnk抑制剂的吡唑并蒽酮及其衍生物和它们的组合物 | |
CN1213306A (zh) | 新的取代咪唑化合物 | |
CN1694704A (zh) | (1h-苯并咪唑-2-基)-(哌嗪基)-甲酮衍生物及其相关化合物作为组胺h4受体拮抗剂用于治疗炎性和过敏性疾病 | |
CN1882345A (zh) | 作为raf激酶抑制剂以治疗癌症的2,6-二取代的喹唑啉、喹喔啉、喹啉和异喹啉 | |
CN1213307A (zh) | 新的取代的咪唑化合物 | |
CN1878759A (zh) | 哒嗪-3(2h)-酮衍生物及其作为pde4抑制剂的用途 | |
CN1636005A (zh) | 苯并噻嗪酮和苯并噁嗪酮化合物 | |
CN1351590A (zh) | 化合物 | |
CN1333754A (zh) | 苯并杂环和它们作为mek抑制剂的用途 | |
CN1356990A (zh) | 双环杂环化合物,含有该化合物的药物组合物,该化合物的用途及其制备方法 | |
CN1906188A (zh) | 作为igf-1r抑制剂的苯基-[4-(3-苯基-1h-吡唑-4-基)-嘧啶-2-基]-胺衍生物 | |
CN1468216A (zh) | 含氮五员环化合物 | |
CN1659145A (zh) | 作为egf-r和her2激酶抑制剂的3-氰基喹啉 | |
CN1886380A (zh) | 苯并咪唑化合物 | |
CN1882571A (zh) | 吡咯衍生物 | |
CN1993358A (zh) | 作为趋化因子受体拮抗剂的噻唑衍生物 | |
CN1113235A (zh) | 苯并咪唑、含这些化合物的药物组合物和其制备方法 | |
CN1478081A (zh) | 取代的2-苯胺基苯并咪唑及其作为nhe抑制剂的用途 | |
CN1906178A (zh) | 喹唑啉衍生物 | |
CN1714078A (zh) | 可用于治疗雄激素受体相关疾病的吲哚类化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ANORMED LTD. Free format text: FORMER OWNER: ANORMED INC. Effective date: 20140326 Owner name: GENZYME CORP. Free format text: FORMER OWNER: ANORMED LTD. Effective date: 20140326 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140326 Address after: Massachusetts, USA Patentee after: GENZYME Corp. Address before: Nova Scotia Canada Patentee before: Arno Ahmed Co.,Ltd. Effective date of registration: 20140326 Address after: Nova Scotia Canada Patentee after: Arno Ahmed Co.,Ltd. Address before: British Columbia Canada Patentee before: Anormed Inc. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20070926 |